No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials

Roon, KI; Olesen, Jes; Diener, HC; Ellis, Peter; Hettiarachchi, J.; H. Poole, P.; Christianssen, I.; Kleinermans, Diane; G. Kok, J.; D. Ferrari, Michel

doi:10.1002/1531-8249(200002)47:2<238::aid-ana15>3.0.co;2-l

Public

No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials

Published in Annals of Neurology • Feb 1, 2000

Authors:

KI Roon

Jes Olesen

HC Diener

Abstract

CP-122,288 is a highly potent inhibitor of neurogenic plasma extravasation in animal models at doses without vasoconstrictor effect. We evaluated the acute antimigraine efficacy of intravenous and oral CP-122,288 in two double-blind studies. In a crossover design, patients randomly received 31.25 mi...

View

Paywalled

Subject

Placebo

Medicine

Extravasation

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions